OnKure Therapeutics, Inc. OKUR Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $458K-26.4% | $622K-22.4% | $802K-14.1% | $934K-13.1% | $1.08M-14.5% | ||
| $458K-27.1% | $628K-21.9% | $804K-13.9% | $934K-13.1% | $1.08M-18.2% | ||
| $11.71M+9.2% | $10.72M-10.0% | $11.92M-5.5% | $12.61M-3.1% | $13.01M-9.4% | ||
| $3.91M+14.8% | $3.41M-5.0% | $3.59M-3.4% | $3.71M-6.9% | $3.99M-8.1% | ||
| $15.62M+10.5% | $14.13M-8.9% | $15.5M-5.0% | $16.32M-4.0% | $17M-9.1% | ||
| $15.62M+10.5% | $14.13M-8.9% | $15.5M-5.0% | $16.32M-4.0% | $17M-9.1% | ||
| -$15.62M-10.5% | -$14.13M+8.9% | -$15.5M+5.0% | -$16.32M+4.0% | -$17M+9.1% | ||
| -$15.16M-12.2% | -$13.5M+8.1% | -$14.7M+4.5% | -$15.39M+3.4% | -$15.93M+8.7% | ||
| -$1.11-12.1% | -$0.99+9.2% | -$1.09+4.4% | -$1.14+4.2% | -$1.19— | ||
| -$1.11-12.1% | -$0.99+9.2% | -$1.09+4.4% | -$1.14+4.2% | -$1.19— | ||
| 13.7M+1.2% | 13.5M-0.1% | 13.5M+0.2% | 13.5M+0.6% | 13.4M+289% | ||
| 13.7M+1.2% | 13.5M-0.1% | 13.5M+0.2% | 13.5M+0.6% | 13.4M+289% | ||
| $458K-26.4% | $622K-22.4% | $802K-14.1% | $934K-13.1% | $1.08M-14.5% | ||
| $458K-27.1% | $628K-21.9% | $804K-13.9% | $934K-13.1% | $1.08M-18.2% | ||
| -$15.62M-10.5% | -$14.13M+8.9% | -$15.5M+5.0% | -$16.32M+4.0% | -$17M+9.1% | ||
| -$15.51M-10.6% | -$14.02M+8.9% | -$15.39M+5.0% | -$16.21M+4.0% | -$16.88M+9.2% | ||
| -$15.51M-10.6% | -$14.02M+8.9% | -$15.39M+5.0% | -$16.21M+4.0% | -$16.88M+9.2% | ||
| -$15.62M-10.5% | -$14.13M+8.9% | -$15.5M+5.0% | -$16.32M+4.0% | -$17M+9.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is OnKure Therapeutics, Inc. profitable?
- OnKure Therapeutics, Inc. is not currently profitable: it reported a net loss of $58.7M over the trailing twelve months.
- What is OnKure Therapeutics, Inc.'s earnings per share?
- OnKure Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $-4.33.
- Where does OnKure Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from OnKure Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.